The efficacy of current-used risk factors for metastasis and the effectiveness of additional surgical resection in pT1b esophageal squamous cell carcinoma after endoscopic resection: A multi-institutional retrospective study in China

Abstract Purpose ER-treated patients with pT1b ESCC were strongly recommended to receive additional treatments, mainly radical surgical resection (SR). In view of high morbidity and mortality of additional SR treatment, this recommendation remained open to debate. Herein, our research aimed to access the efficacy of current risk predictors for metastasis based on the histological findings in ER specimens, and the effectiveness of additional SR. Methods We conducted a retrospective study of ER-treated pT1b ESCC patients with (n = 42) and without (n = 124) additional SR from 2007 to 2018 in China. Lymph node metastasis & distant organ metastasis (LNM&DOM) reflecting the overall metastasis risk of ESCC after ER treatment were used. The relationships between clinicopathological parameters and metastasis were assessed. And Overall survival(OS) and progression-free survival (PFS) were also analyzed. Results Patients with submucosal invasion depth (SMI) ≥ 200µm didn't demonstrate significant difference in LNM&DOM and survival, as compared with those with SMI < 200µm.In ER alone group, patients with vertical margin(VM) (+) showed worse PFS than those with VM(-) (p = 0.008).More strikingly, for patients in low-risk group who had LVI(-) and VM(-), ER + SR didn't significantly prolong their PFS(p = 0.120) but significantly shorter their OS (p < 0.010) as compared with ER alone treatment. Conclusions SMI ≥ 200µm isn’t a sensitive and predictive indicator for both LNM&DOM and survival for patients with ER treatment. More strikingly, additional SR is not an optimal therapeutic selection for ER-treated pT1b ESCC in low-risk group who had LVI(-) and VM(-).

Download Full-text

The influence of age and comorbidities on the outcomes of surgical treatment with free tissue transfer: a retrospective study

Otolaryngologia Polska ◽

10.5604/01.3001.0014.0226 ◽

2020 ◽

Vol 74 (4) ◽

pp. 8-12

Author(s):

Małgorzata Czesak ◽

Maria Sobol ◽

Antoni Bruzgielewicz ◽

Kazimierz Niemczyk ◽

Ewa Osuch-Wójcikiewicz

Keyword(s):

Retrospective Study ◽

High Risk ◽

Head And Neck ◽

Free Flap ◽

Risk Group ◽

Free Tissue Transfer ◽

Low Risk ◽

Local Complications ◽

Tissue Transfer ◽

Significant Difference

Introduction: Microvascular free tissue transfer enables the reconstruction of complex head and neck defects. The aim of the study was to assess the results of treatment of patients undergoing reconstructive surgery and to identify factors affecting these results, with particular reference to patient’s age. Materials and Methods: All patients who underwent free-flap head and neck reconstruction in our institution between 2010 and 2017 were included in this retrospective study. A series of 66 patients met the inclusion criteria and were divided into 2 age groups: group G1 aged <65 years (n = 41) and group G2 aged ≥65 years (n = 25). Minor local complications and general complications as well as comorbidities were analyzed. Results: No correlation was found between advanced age and the risk of free flap failure as well as the incidence of local minor complications. General complications were more frequent in the G2 group (32%) than in the G1 group (19.5%), although this is not a statistically significant difference. A statistically significant difference was found between the age and the patient’s health status according to ASA (P = 0.010). In the younger low-risk group, 12 patients (29.3%) had general and local complications, while in the older low-risk group only 1 (4%). General and local complications were found in 5 (12.2%) high-risk G1 patients and in 7 (28%) high-risk G2 patients. Conclusion(s): Patients with advanced head and neck malignant tumors should undergo reconstructive microsurgery regardless of age.

Download Full-text

The GALNT14 Genotype Predicts Postoperative Outcome of Pancreatic Ductal Adenocarcinoma

Journal of Clinical Medicine ◽

10.3390/jcm8122225 ◽

2019 ◽

Vol 8 (12) ◽

pp. 2225 ◽

Cited By ~ 2

Author(s):

Chun-Cheng Chiang ◽

Chau-Ting Yeh ◽

Tsann-Long Hwang ◽

Yu-De Chu ◽

Siew-Na Lim ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Surgical Resection ◽

Prognostic Marker ◽

Postoperative Outcome ◽

Progression Free Survival ◽

Ductal Adenocarcinoma ◽

Clinicopathological Parameters ◽

Negative Resection Margin ◽

Response To Chemotherapy ◽

Significant Difference

Pancreatic ductal adenocarcinoma (PDA) is notorious for its poor prognosis. The current mainstay of treatment for PDA is surgical resection followed by adjuvant chemotherapy. However, it is difficult to predict the post-operative outcome because of the lack of reliable markers. The single-nucleotide polymorphism (SNP) of N-acetylgalactosaminyltransferase14 (GALNT14) has been proven to predict the progression-free survival (PFS), overall survival (OS) and response to chemotherapy in various types of gastrointestinal (GI) cancers. However, its role in PDA has not been studied. This study aims to investigate whether the GALNT14 SNP genotype can be a prognostic marker for PDA. A cohort of one hundred and three PDA patients having received surgical resection were retrospectively enrolled. GALNT14 genotypes and the clinicopathological parameters were correlated with postoperative prognosis. The genotype analysis revealed that 19.4%, 60.2% and 20.4% of patients had the GALNT14 “TT”, “TG” and “GG” genotypes, respectively. The patients with the “GG” genotype had a mean OS time of 37.1 months (95% confidence interval [CI]: 18.2–56.1) and those with the “non-GG” genotype had a mean OS time of 16.1 months (95% CI: 13.1–19.2). Kaplan–Meier analysis showed that the “GG” genotype had a significantly better OS compared to the “non-GG” genotype (p = 0.005). However, there was no significant difference between the “GG” and “non-GG” genotypes in PFS (p = 0.172). The baseline characteristics between patients with the “GG” and “non-GG” genotypes were compared, and no significant difference was found. Univariate followed by multivariate Cox proportional hazard models demonstrated the GALNT14 “GG” genotype, negative resection margin, and locoregional disease as independent predictors for favorable OS (p = 0.003, p = 0.037, p = 0.021, respectively). Sensitivity analysis was performed in each subgroup to examine the relationship of GALNT14 with different clinicopathological variables and no heterogeneity was found. The GALNT14 “GG” genotype is associated with favorable survival outcome, especially OS, in patients with resected PDA and could serve as a prognostic marker.

Download Full-text

Prognostic significance of peritoneal cytology in low-risk endometrial cancer: comparison of laparoscopic surgery and laparotomy

International Journal of Clinical Oncology ◽

10.1007/s10147-020-01854-z ◽

2021 ◽

Author(s):

Satoe Fujiwara ◽

Ruri Nishie ◽

Shoko Ueda ◽

Syunsuke Miyamoto ◽

Shinichi Terada ◽

...

Keyword(s):

Endometrial Cancer ◽

Laparoscopic Surgery ◽

Retrospective Study ◽

Prognostic Significance ◽

Low Risk ◽

Peritoneal Cytology ◽

Chi Square ◽

Significant Difference ◽

Chi Square Test ◽

Positive Peritoneal Cytology

Abstract Background There is uncertainty surrounding the prognostic value of peritoneal cytology in low-risk endometrial cancer, especially in laparoscopic surgery. The objective of this retrospective study is to determine the prognostic significance of positive peritoneal cytology among patients with low-risk endometrial cancer and to compare it between laparoscopic surgery and conventional laparotomy. Methods From August 2008 to December 2019, all cases of pathologically confirmed stage IA grade 1 or 2 endometrial cancer were reviewed at Osaka Medical College. Statistical analyses used the Chi-square test and the Kaplan–Meier log rank. Results A total of 478 patients were identified: 438 with negative peritoneal cytology (232 who underwent laparotomy and 206 who undertook laparoscopic surgery) and 40 with positive peritoneal cytology (20 who underwent laparotomy and 20 who received laparoscopic surgery). Survival was significantly worse among patients with positive peritoneal cytology compared to patients with negative peritoneal cytology. However, there was no significant difference among patients with negative or positive peritoneal cytology between laparoscopic surgery and laparotomy. Conclusion This retrospective study suggests that, while peritoneal cytology is an independent risk factor in patients with low-risk endometrial cancer, laparoscopic surgery does not influence the survival outcome when compared to laparotomy.

Download Full-text

Clinical and Biological Prognostic Factors in Follicular Lymphoma Patients During Treatment

10.21203/rs.3.rs-275643/v1 ◽

2021 ◽

Author(s):

Ádám Jóna ◽

Anna Kenyeres ◽

Sándor Barna ◽

Árpád Illés ◽

Zsófia Simon

Keyword(s):

Prognostic Factors ◽

High Risk ◽

Follicular Lymphoma ◽

Risk Group ◽

Standardized Uptake Value ◽

Progression Free Survival ◽

High Risk Group ◽

Pet Ct ◽

Significant Difference ◽

Biological Prognostic Factors

Abstract Introduction: Follicular lymphoma (FL) is an indolent yet heterogeneous B-cell lymphoproliferative disorder. Most people respond to treatment well. However, a particular group of patients has a poor prognosis, and these patients are difficult to define.Patients and methods: We retrospectively analyzed FL patients treated at the University of Debrecen in the past 20 years. We investigated prognostic factors that may influence the survival of FL patients.Results: We found a standardized uptake value (SUV)max cut-off value of 9.85 at the staging PET/CT to significantly separate FL patients’ progression-free survival (PFS) (p=0.0003, HR: 0.2560, 95%CI: 0.1232-0.5318). Lymphocyte/ monocyte (Ly/Mo) ratio of 3.45 drawn at diagnosis also significantly predicted PFS (p=0.0324, HR: 1.806, 95% CI: 1.051-3.104). Combining patients’ with staging SUVmax >9.85 and Ly/Mo < 3.45 a high-risk group of FL patients can be identified (p<0.0001, HR: 0.1033, 95%CI: 0.03719-0.2868). Similarly, a significant difference was shown with a SUVmax cut-off of 3.15 at the interim PET/CT (p<0.0001, HR: 0.1535, 95%CI: 0.06329-0.3720). Combining patients with staging SUVmax >9.85 and interim SUVmax >3.15, a high-risk group of FL patients can be identified (p<0.0001, HR: 0.1037, 95%CI: 0.03811-0.2824). The PFS difference is translated into overall survival advantage (p=0.0506, HR: 0.1187, 95%CI: 0.01401-1.005).Discussion: Biological prognostic factors, such as the Ly/ Mo ratio, may improve the prognostic assessment of staging PET/CT. Nevertheless, PFS difference is translated into OS when using a combination of staging and interim SUVmax. We consider investigating additional biological prognostic factors while currently highlighting PET/CT's role in FL.

Download Full-text

Transition of molecular target agent therapy in advanced hepatocellular carcinoma: A multicenter, retrospective study.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.3_suppl.317 ◽

2021 ◽

Vol 39 (3_suppl) ◽

pp. 317-317

Author(s):

Kazufumi Kobayashi ◽

Sadahisa Ogasawara ◽

Aya Takahashi ◽

Yuya Seko ◽

Satoshi Tsuchiya ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Retrospective Study ◽

Performance Status ◽

Progression Free Survival ◽

Staging System ◽

Sequential Therapy ◽

Molecular Target ◽

Advanced Hepatocellular Carcinoma ◽

Entire Cohort ◽

Significant Difference

317 Background: There have been considerable advances in systemic chemotherapy for hepatocellular carcinoma (HCC) in recent times. Currently, four molecular target agents (MTA) are available for HCC treatment in Japan. Sequential therapy using multiple MTAs is being considered as the gold standard of treatment. However, the effectiveness of the treatment strategy transition for HCC remains unclear. The present study aimed to clarify the current practical use of MTAs and its effectiveness in HCC treatment. Methods: In this multicenter, retrospective study, we collected and analyzed the clinical data of 877 patients who underwent MTA therapy for HCC from June 2009 to March 2019 at several institutes in Japan. The patients were classified into 3 groups as per the period of initial MTA treatment beginning (period 1: 2009–2012, n = 267; period 2: 2013–2016, n = 352; period 3: 2017–2019, n = 258). These 3 periods were defined to have approximately same term. Period 3 means the era of multiple MTAs because of the approval of regorafenib in Japan in 2017. We assessed the patient characteristics, MTA use, and prognosis of the 3 groups. Results: The proportion of patients with advanced-stage HCC, defined according to the Barcelona Clinic Liver Cancer staging system, in each period was 70.1%, 66.5%, and 62.0% in period 1, 2, and 3, respectively. MTA use for intermediate stages increased with the passage of time ( p = 0.052). The proportion of multiple MTAs use was remarkably increased in the 3 groups (1.1%, 10.2%, and 42.6%, respectively, p < 0.0001). Child-Pugh score, proportion of macrovascular invasion, extrahepatic metastasis, and α-fetoprotein (AFP) ≥400 ng/mL showed no significant difference among the 3 groups. The median overall survival was 11.9 months for the entire cohort and 10.4, 11.3, and 15.2 months, for period 1, 2, and 3, respectively. It is noteworthy that the prognosis of patients with HCC improved over time ( p = 0.016). With respect to progression-free survival, the median value was 3.0 months for the entire cohort and 2.7, 2.8, and 4.7 months for period 1, 2, and 3, respectively ( p < 0.0001). The treatment duration was also prolonged with time (2.7, 3.2, and 6.6 months for period 1, 2, and 3, respectively; p < 0.0001). Multivariate analysis using Cox proportional hazard model showed that HCV infection, Child-Pugh score, performance status, α-fetoprotein ≥400 ng/mL, presence of macrovascular invasion, and period 3 for initial MTA introduction were independent prognostic factors. Conclusions: Sequential therapy with multiple MTAs has gained popularity with time and is considered to improve patient prognosis. The development of MTA therapy for HCC is expected to continue. Therefore, further studies are needed to help determine the appropriate drugs, the sequence of MTA use, and the precise transition time.

Download Full-text

Prognosis-Related Autophagy Genes in Female Lung Adenocarcinoma

10.21203/rs.3.rs-53994/v1 ◽

2020 ◽

Author(s):

Zhongxiang Liu ◽

Haicheng Tang ◽

Yongqian Jiang ◽

Xiaopeng Zhan ◽

Sheng Kang ◽

...

Keyword(s):

Survival Rate ◽

Lung Adenocarcinoma ◽

Regression Model ◽

Clinical Data ◽

Risk Score ◽

Risk Group ◽

Risk Scores ◽

Clinicopathological Parameters ◽

Significant Difference ◽

Cox Analysis

Abstract Background: To screen the prognosis-related autophagy genes of female lung adenocarcinoma by the transcriptome data and clinical data from TCGA database.Methods: In this study, Screen meaningful female lung adenocarcinoma differential genes in TCGA, use univariate COX proportional regression model to select genes related to prognosis, and establish the best risk model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied for carrying out bioinformatics analysis of gene function.Results: The gene expression and clinical data of 260 female lung adenocarcinoma patient samples were downloaded from TCGA. 12 down-regulated genes: NRG3, DLC1, NLRC4, DAPK2, HSPB8, PPP1R15A, FOS, NRG1, PRKCQ, GRID1, MAP1LC3C, GABARAPL1. Up-regulated 15 genes: PARP1, BNIP3, P4HB, ATIC, IKBKE, ITGB4, VMP1, PTK6, EIF4EBP1, GAPDH, ATG9B, ERO1A, TMEM74, CDKN2A, BIRC5. GO and KEGG analysis showed that these genes were significantly associated with autophagy and mitochondria (animals). Multi-factor COX analysis of autophagy-related genes showed that ITGA6, ERO1A, FKBP1A, BAK1, CCR2, FADD, EDEM1, ATG10, ATG4A, DLC1, VAMP7, ST13 were identified as independent prognostic indicators. According to the multivariate COX proportional hazard regression model, there was a significant difference in the survival rate observed between the high-risk group (n=124) and the low-risk group (n=126) during the 10-year follow-up (p<0.05). Univariate COX analysis showed that tumor stage, T, M and N stages, and risk score were all related to the survival rate of female lung adenocarcinoma patients. Multivariate COX analysis found that autophagy-related risk scores were independent predictors, with an AUC value of 0.842. At last, there are autophagy genes differentially expressed among various clinicopathological parameters: ATG4A, BAK1, CCR2, DLC1, ERO1A, FKBP1A, ITGA6.Conclusion: The risk score can be used as an independent prognostic indicator for female patients with lung adenocarcinoma. The autophagy genes ITGA6, ERO1A, FKBP1A, BAK1, CCR2, FADD, EDEM1, ATG10, ATG4A, DLC1, VAMP7, ST13 were identified as prognostic genes in female lung adenocarcinoma, which may be the targets of treatment in the future.

Download Full-text

Computational identification of mutator-derived lncRNA signatures of genome instability for improving the clinical outcome of cancers: a case study in breast cancer

Briefings in Bioinformatics ◽

10.1093/bib/bbz118 ◽

2019 ◽

Vol 21 (5) ◽

pp. 1742-1755 ◽

Cited By ~ 26

Author(s):

Siqi Bao ◽

Hengqiang Zhao ◽

Jian Yuan ◽

Dandan Fan ◽

Zicheng Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Genomic Instability ◽

Genome Instability ◽

Risk Group ◽

Expression Profiles ◽

Risk Groups ◽

Low Risk ◽

A Genome ◽

Significant Difference

Abstract Emerging evidence revealed the critical roles of long non-coding RNAs (lncRNAs) in maintaining genomic instability. However, identification of genome instability-associated lncRNAs and their clinical significance in cancers remain largely unexplored. Here, we developed a mutator hypothesis-derived computational frame combining lncRNA expression profiles and somatic mutation profiles in a tumor genome and identified 128 novel genomic instability-associated lncRNAs in breast cancer as a case study. We then identified a genome instability-derived two lncRNA-based gene signature (GILncSig) that stratified patients into high- and low-risk groups with significantly different outcome and was further validated in multiple independent patient cohorts. Furthermore, the GILncSig correlated with genomic mutation rate in both ovarian cancer and breast cancer, indicating its potential as a measurement of the degree of genome instability. The GILncSig was able to divide TP53 wide-type patients into two risk groups, with the low-risk group showing significantly improved outcome and the high-risk group showing no significant difference compared with those with TP53 mutation. In summary, this study provided a critical approach and resource for further studies examining the role of lncRNAs in genome instability and introduced a potential new avenue for identifying genomic instability-associated cancer biomarkers.

Download Full-text

Proteomic Pattern-Based Risk Stratification of Outcome Shows Significant Higher Accuracy Compared to HCT-CI in Patients with AML and MDS,

Blood ◽

10.1182/blood.v118.21.4128.4128 ◽

2011 ◽

Vol 118 (21) ◽

pp. 4128-4128

Author(s):

Christiane E Dobbelstein ◽

Jochen Metzger ◽

Elke Dammann ◽

Uwe Borchert ◽

Stefanie Buchholz ◽

...

Keyword(s):

Risk Stratification ◽

Cell Transplantation ◽

Hematopoietic Cell Transplantation ◽

Risk Group ◽

Risk Groups ◽

Low Risk ◽

The Other ◽

Unrelated Donor ◽

Intermediate Risk ◽

Significant Difference

Abstract Abstract 4128 Objectives: Allogeneic stem cell transplantation (SCT) is an established treatment for many severe disorders of hematopoiesis. Although SCT has considerable curative potential, its application is limited by transplant-related complications such as infections and graft-versus host disease (GvHD) which could lead to high mortality rates especially in older or less fit patients. Therefore, a careful pre-SCT assessment of risk and benefit is mandatory and different scores have recently emerged as helpful tools. We have previously applied proteomics to identify a specific urinary polypeptide patterns (PP) predictive for developing acute GvHD (aGvHD) (Weissinger EM et al, Blood 2007;109:5511–5519). The aim of this study was to investigate whether the PPs can predict overall outcome after allo-SCT and to compare these findings to those of the hematopoietic cell transplantation comorbidity index (HCT-CI) (Sorror M et al, Blood 2005;106:2912–2919). Methods: In this retrospective analysis from Hannover Medical School, the datasets from all patients (pts) with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), who were allo-transplanted from a fully matched donor (matched related/unrelated donor (MRD/MUD)) between 2003–2008 and for whom relevant PP data were available, were included. Pts with a pt-donor HLA-mismatch constellation were excluded from this study. PP data from urine samples which were prospectively collected by day ≥ +7 after allo-SCT were correlated with overall survival (OS), aGvHD, non-relapse mortality (NRM), relapse rate and mortality (RM), and compared to the predictive value of the HCT-CI. Results: PP data were available from 111 pts (97 pts with AML, 14 with MDS; median age 52y; median EBMT score 4; 59 male/52 female; 69 MUD/42 MRD). They were grouped in high (PP-HRG), low (PP-LRG) or intermediate risk groups (PP-IRG). Forty-three pts (39%) belonged to the PP-LRG for aGvHD compared to 47 pts (42%) who were classified PP-HRG. Patient characteristics of PP-LRG and PP-HRG were similar in terms of age, sex and EBMT score (median 4 in both groups). OS compared favorably for the PP-LRG with an OS of 72% vs. 49% for the PP-HRG (p=0.03), also if only reduced intensity conditioning (RIC) was considered (73% vs 42%; p=0.01), respectively. There was a trend for higher incidence of NRM in the PP-HRG compared to PP-LRG (30% vs 14%, p=0.07) for the whole cohort, and a significant higher NRM rate, if only RIC was evaluated (35% vs 11%, p=0.01). However, if risk stratification was based on the HCT-CI, there was no significant difference between high risk (S-HRG) and low risk group (S-LRG) in terms of OS and NRM regardless of intensity of conditioning (OS for whole cohort: 57% vs 45%, p=0.4; OS for RIC: 56% vs 36%, p=0.2; NRM for whole cohort: 20% vs 23%, p=0.8; NRM for RIC: 18% vs 29%, p=0.4). Concerning the PP-IRG, there was a difference in OS between PP-IRG and PP-LRG (38% vs 73%, p=0.02). However, there was no significant difference in OS of the PP-IRG compared to the other PP-based risk groups nor between the HCT-CI based risk groups. Further, NRM did not show a significant difference neither for PP-based nor HCT-CI-based intermediate risk group compared to the other risk groups. Thirty vs 15 pts developed aGvHD in PP-HRG and PP-LRG (64% vs 35%, p<0.01) compared to 48% vs 64% (p=0.2) for S-HRG and S-LRG of the whole cohort, respectively. Incidence of aGvHD differed also significantly in the RIC cohort for PP-HRG and PP-LRG (65% vs 32%, p=0.01), but not for HCT-CI-based risk groups (47% vs 64%, p=0.1). Relapse rates and RM were not significantly different between high and low risk groups, neither for PP-based nor HCT-CI based (whole cohort and RIC subgroup), respectively. Conclusion: Risk stratification according to GvHD-match based PP, which has previously been shown to predict aGvHD, now also allows the identification of patient groups with significantly different OS and NRM. In comparison to the HCT-CI, PP-based prediction shows significantly higher accuracy in this rather homogeneous cohort of patients. Since proteomics is a new method which has been available only at a few centers, further multicenter analyses are essential to determinate the value of PP-based prediction of complications and outcome in SCT. Disclosures: Metzger: Mosaiques Diagnostics GmbH: Employment.

Download Full-text

Development of An Inflammatory Response-Related Gene Signature To Predict Prognosis and Immunotherapy Response For Patients With Glioma

10.21203/rs.3.rs-1056221/v1 ◽

2021 ◽

Author(s):

Zhen Zhao ◽

Jianglin Zheng ◽

Yi Zhang ◽

Xiaobing Jiang ◽

Chuansheng Nie ◽

...

Keyword(s):

Inflammatory Response ◽

Cox Regression ◽

Risk Group ◽

Gene Signature ◽

Low Risk ◽

Normal Brain ◽

Related Gene ◽

Who Grade ◽

Cox Regression Analysis ◽

Significant Difference

Abstract Inflammatory response plays a crucial role in the development and progression of gliomas. However, the prognostic value of inflammatory response-related genes has never been comprehensively investigated for glioma. In this study, we identified 39 differentially expressed genes (DEGs) between glioma and normal brain tissue samples, of which 31 inflammatory response-related genes are related to the prognosis of glioma., The 8 optimal inflammatory response-related genes were selected to construct prognostic inflammatory response-related gene signature (IRGS) through the least absolute shrinkage and selection operator (LASSO) penalized Cox regression analysis. The effectiveness of the IRGS was verified in the training (TCGA) and validation (CGGA-693 CGGA-325 and Rembrandt) cohorts. The Kaplan-Meier curve revealed a significant difference in the OS between the high- and low-risk groups. The receiver operating characteristic curve (ROC) shows the powerful predictive ability of IRGS. Meanwhile, a nomogram with better accuracy was established to predict overall survival (OS) based on the independent prognostic factors (IRGS, age, WHO grade, and 1p19q codeletion). In addition, patients in the high-risk group had higher immune, stroma, and ESTIMATE scores, lower tumor purity, higher infiltration of immunosuppressive cells, higher expression of immune checkpoints, higher expression of TIDE and Exclusion, and lower expression of MSI Expe Sig. Thus, the patients in the low-risk group had significantly higher respond rate of immune checkpoint inhibitors (ICIs). A novel prognostic signature incorporated 8 inflammatory response-related genes was associated with the prognosis, immune landscape and the immunotherapy response in patients with gliomas. Thus, the signature can be suitable for future clinical application to predict the prognosis of patients with glioma.

Download Full-text

Complete Identification of Autophagy-Related lncRNA Prognostic Signature for Breast Cancer

10.21203/rs.3.rs-347298/v1 ◽

2021 ◽

Author(s):

Wenxi Wang ◽

Na Li ◽

Lin Shen ◽

Qin Zhou ◽

Zhanzhan Li ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Model ◽

Immune Cell ◽

Risk Group ◽

Pearson Correlation ◽

Risk Groups ◽

Cell Types ◽

High Risk Group ◽

Low Risk ◽

High Morbidity

Abstract Purpose: Breast cancer (BC) has a relatively high morbidity and mortality for women. The research about BC prognosis is significant. Autophagy is an essential process for tumor progression, which could play its role with lncRNA, a kind of ncRNA that have regulatory roles in multiple tumors. Therefore, constructing an autophagy-related prognostic model for breast cancer is meaningful.Methods: We download data from the TCGA and HADb. Pearson correlation analysis was performed to excavate autophagy-related lncRNA. Then with gene expression difference analysis, etc. we explored the relationship between clinical features and the signature. We applied Cytoscape as well as KEGG, etc. to explore expression condition. And the autophagy status of our signature was investigated by GSEA, etc. We also searched the immune distinction by CIBERSORTx to extend our study and preliminarily verified our study in the end.Results: Firstly, we got an independent autophagy-related lncRNA prognostic model, by which BC patients were divided into high- and low-risk groups. We found that the OS of high-risk group is significantly lower than that of low-risk group, which was identical to those within various clinical subgroups. Then, the KEGG and GO analysis enriched several pathways including autophagy. PCA and GSEA analysis demonstrated the autophagy status. Several distinguishing immune cell types in separated groups were revealed by immunity analysis. Then the verification in the end proved the feasibility of our signature.Conclusion: In this study, we acquired an independent autophagy-related lncRNA signature involving 12 lncRNAs, which contributes to the prediction of prognosis of BC patients.

Download Full-text